郭艳美女士由第八届董事会非职工代表董事变更为第八届董事会职工代表 董事，任期至第八届董事会任期届满之日止。本次选举完成后，公司董事会中兼 任高级管理人员职务的董事以及由职工代表担任的董事总计不超过公司董事总 数的二分之一。 特此公告。 深圳迈瑞生物医疗电子股份有限公司董事会 2025 年 5 月 20 日 证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-019 深圳迈瑞生物医疗电子股份有限公司 关于选举产生第八届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司章程指 引》等法律法规及《深圳迈瑞生物医疗电子股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，为保证深圳迈瑞生物医疗电子股份有限公司（以下简称 "公司"或"迈瑞医疗"）董事会的合规运作，公司于 2025 年 5 月 20 日召开了 职工代表大会，经与会职工代表审议，一致同意选举郭艳美女士（简历见附件） 担任公司第八届董事会职工代表董事。 郭艳美，女，1963 年出生，中国国籍，无境外永久 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-018 一、重要提示 1. 本次股东大会未出现否决议案的情形。 2. 本次股东大会不涉及变更以往股东大会决议。 二、会议召开情况 （一）会议召开时间 （1）现场会议：2025年5月20日15:00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年5月20 日9:15-9:25、9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的具 体时间为：2025年5月20日9:15至15:00期间的任意时间。 深圳迈瑞生物医疗电子股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 （二）现场会议召开地点：深圳市南山区高新技术产业园区科技南十二路迈瑞总部大厦会 议室 （三）会议召集人 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）董事会 （四）投票方式 本次会议采取现场投票与网络投票相结合的方式召开。 本次股东大会通过深圳证券交易所交易系统和互联网投票系统向社会公众股股东提供网 络形式的投票平台 ...

Group 1 - The core viewpoint of the articles highlights that Mindray Medical's stock closed at 223.72 yuan, down 1.01%, with a rolling PE ratio of 24.36 times and a total market capitalization of 271.25 billion yuan [1] - The average PE ratio for the medical device industry is 49.51 times, with a median of 36.17 times, placing Mindray Medical at the 53rd position in the industry ranking [1] - As of March 31, 2025, Mindray Medical had 92,191 shareholders, an increase of 9,446 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Mindray Medical's main business includes the research, manufacturing, marketing, and service of medical devices, with key products in life information and support, in vitro diagnostics, medical imaging, electrophysiology, and vascular intervention [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 8.237 billion yuan, a year-on-year decrease of 12.12%, and a net profit of 2.629 billion yuan, down 16.81%, with a gross profit margin of 62.53% [1] - The PE ratios for Mindray Medical are 24.36 (TTM) and 23.25 (static), with a price-to-book ratio of 7.03 [2]

截至5月20日收盘，宠物经济概念上涨4.08%，位居概念板块涨幅第2，板块内，83股上涨，天元宠物、 创源股份等20%涨停，贝因美、依依股份、实丰文化等涨停，路斯股份、驱动力、美农生物等涨幅居 前，分别上涨18.10%、14.10%、13.81%。跌幅居前的有哈三联、新华制药、狮头股份等，分别下跌 3.49%、3.23%、3.01%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 培育钻石 | 4.10 | 航运概念 | -1.44 | | 宠物经济 | 4.08 | 中韩自贸区 | -1.24 | | 动物疫苗 | 4.00 | 成飞概念 | -1.16 | | 重组蛋白 | 3.90 | PEEK材料 | -0.75 | | IP经济(谷子经济) | 3.45 | 自由贸易港 | -0.68 | | 人造肉 | 3.14 | 钛白粉概念 | -0.58 | | 托育服务 | 2.95 | 碳纤维 | -0.34 | | 兵装重组概念 | 2.75 | 太赫兹 | -0.23 | | NFT概念 | 2. ...

Core Viewpoint - The domestic medical device market is experiencing rapid growth driven by new infrastructure in healthcare, but concerns about future growth rates have emerged due to local fiscal challenges [1][2]. Group 1: Company Performance and Market Dynamics - Mindray Medical held an online performance briefing on May 16, addressing investor concerns about the impact of local fiscal pressures on hospital equipment procurement [1]. - The company noted that while local fiscal constraints are currently affecting procurement, the issuance of local special bonds has been increasing since Q1 2023, which is expected to alleviate some of these pressures [1]. - Data from Zhongcheng Medical indicates a recovery in monthly bidding for various medical devices since December 2024, although the time from bidding to revenue recognition has significantly lengthened [1]. Group 2: Procurement and Financial Data - In April, the results of the Hainan Province 2024 long-term special bond project for medical equipment procurement showed that 200 ultrasound devices were bid for, with a total budget of 190 million yuan, and Mindray won 7 packages totaling 160 devices for nearly 99 million yuan [2]. - The issuance of medical special bonds, particularly for hospital renovations and equipment procurement, has seen significant growth, with a 42.18% year-on-year increase in March 2025 [2]. Group 3: Long-term Outlook - Mindray Medical remains optimistic about the domestic market, citing long-term trends such as population aging and rising income levels that will drive demand for quality medical resources [2]. - The company is expanding its market reach through internal R&D and external acquisitions, focusing on "equipment + IT + AI" digitalization, and aims to enhance its presence in high-end markets [2]. - Analysts from Huazhong Securities and Puyin International Securities predict a rebound in Mindray's domestic market growth starting in Q3 2023, supported by easing fiscal pressures and the initiation of medical equipment update projects [3].

Market Overview - The FTSE China A50 index components showed mixed performance with logistics, chemical pharmaceuticals, and home appliances leading in gains, while the coal sector faced declines [1] Sector Performance Insurance - China Pacific Insurance, China Ping An, and China Life Insurance reported market capitalizations of 980.99 billion, 361.31 billion, and 326.32 billion respectively, with trading volumes of 6.54 million, 10.71 million, and 5.58 million [3] Alcohol Industry - Kweichow Moutai, Shanxi Fenjiu, and Wuliangye had market capitalizations of 1993.60 billion, 242.98 billion, and 501.66 billion respectively, with trading volumes of 18.64 million, 10.49 million, and 5.22 million [3] Semiconductor - Northern Huachuang, Cambricon Technologies, and Haiguang Information had market capitalizations of 231.43 billion, 284.52 billion, and 325.85 billion respectively, with trading volumes of 7.93 million, 15.80 million, and 6.32 million [3] Automotive - BYD, Great Wall Motors, and Beijing-Shanghai High-speed Railway reported market capitalizations of 1192.71 billion, 199.78 billion, and 294.15 billion respectively, with trading volumes of 37.01 million, 1.61 million, and 2.02 million [3] Oil Industry - COSCO Shipping, Sinopec, and China National Petroleum had market capitalizations of 687.67 billion, 1498.94 billion, and 254.36 billion respectively, with trading volumes of 2.16 million, 2.49 million, and 14.71 million [3] Coal Industry - China Shenhua, Shaanxi Coal and Chemical Industry, and CATL reported market capitalizations of 194.68 billion, 1198.11 billion, and 777.26 billion respectively, with trading volumes of 3.11 million, 3.58 million, and 50.90 million [3] Power Industry - Dongfang Electric, Yangtze Power, and China Nuclear Power had market capitalizations of 753.62 billion, 197.66 billion, and 341.13 billion respectively, with trading volumes of 10.66 million, 7.40 million, and 21.45 million [4] Food and Beverage - CITIC Securities, Guotai Junan, and Haitian Flavoring reported market capitalizations of 387.85 billion, 311.87 billion, and 240.72 billion respectively, with trading volumes of 1.95 million, 7.07 million, and 2.48 million [4] Consumer Electronics - Industrial Fulian, Luxshare Precision, and Heng Rui Medicine had market capitalizations of 379.50 billion, 235.47 billion, and 348.74 billion respectively, with trading volumes of 3.94 million, 17.94 million, and 15.65 million [4] Home Appliances - Gree Electric, Haier Smart Home, and Muyuan Foods reported market capitalizations of 261.19 billion, 245.55 billion, and 216.54 billion respectively, with trading volumes of 11.37 million, 5.03 million, and 4.47 million [4] Medical Devices - Mindray Medical, Wanhua Chemical, and SF Holding had market capitalizations of 178.50 billion, 224.01 billion, and 272.74 billion respectively, with trading volumes of 9.22 million, 6.67 million, and 4.36 million [4] Telecommunications - China Construction, China Unicom, and China Telecom had market capitalizations of 235.94 billion, 171.33 billion, and 466.44 billion respectively, with trading volumes of 11.23 million, 2.30 million, and 8.29 million [4] Transportation Equipment - China CRRC and Guodian NARI had market capitalizations of 209.50 billion and 184.02 billion respectively, with trading volumes of 1.15 million and 2.30 million [5]

二、中国政策支持成长性企业的发展，带动全球资产加强对创业板指的关注 国家持续推动科技创新和产业升级，创业板聚焦"三创四新"（创新、创造、创意，新技术、新产业、新 业态、新模式），战略性新兴产业占比较高，受益于国家对成长行业、新型科技行业的支持。 专题：专题｜深交所2025全球投资者大会：投资中国就是投资未来 5月19日，由深交所主办的2025全球投资者大会在深圳举行。中国证监会副主席李明在会上致辞时表 示，近期，证监会将出台深化科创板、创业板改革政策措施，为企业创新成长提供更加适配、更加包容 的制度支撑。接下来还将持续引导上市公司积极通过现金分红、回购增持、并购重组等方式提升投资价 值，不断打造高质量、有活力的上市公司群体，为全球投资者提供更多优质的投资标的。 近年来，创业板指ETF规模呈现快速增长态势，从2020年初的约200亿元增长至如今的近1200亿元。对 于创业板ETF展现强大"吸金能力"的关键支撑，富国基金创业板ETF基金经理曹璐迪认为主要有以下三 大因素： 一、创业板指成分股汇聚了国内新经济领域的核心资产，所以创业板ETF是国内外投资者关注中国成长 龙头公司的重要方式 创业板指汇聚了中国新经济领域 ...

Group 1 - The core viewpoint of the news is the performance and structure of the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A, which has experienced a slight decline recently [1] - As of May 19, the fund's latest net value is 1.05 yuan, marking a continuous drop for four trading days with a cumulative decline of 1.26% [1] - The fund was established in August 2024 with a total size of 0.13 billion yuan and has achieved a cumulative return of 4.82% since inception [1] Group 2 - The fund's holder structure shows that institutional investors hold 0.10 billion shares, accounting for 91.94% of the total shares, while individual investors hold 0.01 billion shares, making up 8.06% [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 41.48%, with major investments in companies such as Mindray Medical (9.10%), Aier Eye Hospital (7.77%), and United Imaging Healthcare (6.36%) [3]

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 278 yuan [2][7]. Core Views - The company is experiencing a structural upgrade towards high-end products and is making significant progress in international markets. The total revenue for 2024 is projected to be 36.726 billion yuan, reflecting a year-on-year growth of 5.14%. The net profit attributable to the parent company is expected to be 11.668 billion yuan, with a slight increase of 0.74% [2][3]. Financial Performance Summary - **2024 Financials**: Total revenue is 36.726 billion yuan, with a year-on-year growth of 5.1%. The net profit attributable to the parent company is 11.668 billion yuan, showing a growth of 0.7% [3]. - **2025 Projections**: Expected revenue growth of 8.4% to 39.827 billion yuan and net profit growth of 7.5% to 12.545 billion yuan [3]. - **2026 and 2027 Outlook**: Revenue is projected to reach 45.883 billion yuan in 2026 and 52.779 billion yuan in 2027, with respective growth rates of 15.2% and 15.0%. Net profit is expected to be 14.832 billion yuan in 2026 and 17.233 billion yuan in 2027, with growth rates of 18.2% and 16.2% [3][8]. Market Dynamics - The international market is showing robust growth, with a 21.28% increase in 2024. The Asia-Pacific region, driven by countries like Australia, Thailand, and India, has seen nearly 40% growth. The European market has rebounded with over 30% growth [7]. - Domestic market performance has been under pressure, with a decline of 5.10% in 2024, primarily due to sluggish procurement processes. However, a rebound is anticipated in Q3 2025 as fiscal conditions improve [7]. Business Segment Performance - **IVD Business**: This segment has shown a growth of 10.82% in 2024, with international IVD growth exceeding 30%. IVD has become the largest business segment, accounting for 37.48% of total revenue [7]. - **Medical Imaging**: This segment grew by 6.60%, with international growth over 15%. The domestic high-end ultrasound market has also seen significant performance [7]. - **Life Information and Support**: This segment faced a decline of 11.11%, but international growth remains strong [7]. Valuation Metrics - The report estimates a DCF-based valuation of 337.1 billion yuan for the company, translating to a target price of approximately 278 yuan, which corresponds to a PE ratio of 27 times for 2025 [7].

Group 1 - The trend of Chinese medical device companies "going global" is long-term positive, especially in the upstream supply chain which has formed a certain scale [1] - In Q1 2025, China's medical device export trade total is projected to reach 69.26 billion yuan, a year-on-year increase of 5.03%, with high-end medical devices seeing significant growth [1] - The export value of China's medical device industry is expected to reach 48.75 billion USD in 2024, reflecting a year-on-year growth of 7.3% [1] Group 2 - Over 100 listed medical device companies have already initiated "going global" operations in 2024, covering various product areas such as medical consumables and diagnostic equipment [2] - Companies are advised to consider business, supply chain, and localization strategies for global expansion [2][3] - Localized production and supply chain management are essential for adapting to market demands in different regions [3] Group 3 - Companies like Haier Bio emphasize the importance of localizing product design and marketing to enhance user experience in overseas markets [4] - The trend of "going global" is common among mature, growth, and startup medical device companies, focusing on high-value and high-end products [6] - High-value medical devices, such as deep brain stimulators, require careful economic calculations and long-term service planning before entering foreign markets [6] Group 4 - Companies are encouraged to leverage digitalization and smart technologies to enhance their global strategies, as seen with Mindray Medical's remote monitoring capabilities [7] - Brand building is crucial for domestic medical device companies, with strategies including sponsorship of international sports events to enhance global influence [7] - The medical device market in Europe and the US accounts for over 65% of the global market share, making it a primary target for Chinese companies [8] Group 5 - Key conditions for Chinese medical device companies to "go global" include having sufficient capital, production capacity, and independent R&D capabilities [8] - Collaboration with local hospitals and doctors for joint R&D and clinical trials can facilitate product entry into new markets [8]